Mirabegron
Brand name: Myrbetriq
Rank #16 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$927.5M
Total Cost
1,407,073
Total Claims
$927.5M
Total Cost
31,017
Prescribers
$659
Cost per Claim
218,887
Beneficiaries
2,130,162
30-Day Fills
$30K
Avg Cost/Provider
45
Avg Claims/Provider
Share of Medicare Part D Spending
0.34%
of total Medicare Part D spending
$927.5M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $927.5M total
🔎 Data Overview
Ranked #16 out of 500 drugs tracked by total cost. Mirabegron represents a significant portion of Medicare drug spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Mirabegron
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Qingwei Yan | Urology | Oakland, CA | 742 | $1.0M |
| 2 | Armen Kassabian | Urology | Burbank, CA | 1,941 | $995K |
| 3 | Victor Hartanto | Urology | Midland Park, NJ | 937 | $814K |
| 4 | Ghazaleh Rostami Nia | Obstetrics & Gynecology | Evanston, IL | 732 | $679K |
| 5 | Theodore Affue | Urology | El Centro, CA | 833 | $662K |
| 6 | Nancy Wilcox | Nurse Practitioner | Rochester, NY | 933 | $655K |
| 7 | Benjamin Peng | Urology | New York, NY | 600 | $625K |
| 8 | Jill Hess | Physician Assistant | Williamsville, NY | 961 | $621K |
| 9 | Manish Gopal | Obstetrics & Gynecology | Somerset, NJ | 990 | $619K |
| 10 | Melissa Fischer | Urology | Royal Oak, MI | 629 | $619K |
| 11 | Scott Macdiarmid | Urology | Greensboro, NC | 854 | $611K |
| 12 | James Renehan | Urology | Tallahassee, FL | 664 | $598K |
| 13 | Natasha Ginzburg | Urology | Syracuse, NY | 770 | $564K |
| 14 | Amy Brode | Urology | Ann Arbor, MI | 592 | $555K |
| 15 | Christopher Kelly | Urology | New York, NY | 798 | $550K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 13 | Bictegrav/Emtricit/Tenofov Ala (Biktarvy) | $1.29B | 310,738 |
| 14 | Etanercept (Enbrel Sureclick) | $1.12B | 145,737 |
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology